$ANRO News

Last published 1d ago

1d agoANROAlto Neuroscience, Inc. - EX-99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
1d agoANROAlto Neuroscience Reports Third Quarter 2026 Financial Results and Recent Business HighlightsBusiness WireMOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today reported financial results for the quarter ended September 30, 2026, and highlighted recent progress across its pipeline of clinical-stage product candidates. “D ...
2mo agoANROAlto Neuroscience Announces Participation in Upcoming Investor ConferencesBusiness WireAlto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of
2mo agoANROAlto Neuroscience Promotes Nick Smith to President and Chief Financial OfficerBusiness WireExpanded role reflects leadership across finance, corporate strategy, and business development Alto Neuroscience, Inc. (NYSE:ANRO), a clinical-stage biopharmaceutical company developing novel precision medicines for
3mo agoANROAlto Neuroscience Reports Second Quarter 2026 Financial Results and Recent Business HighlightsBusiness Wire– ALTO-207 development expanded: an additional Phase 3 trial evaluating ALTO-207 as monotherapy in treatment-resistant depression (TRD) is now planned, alongside the ongoing potentially registrational Phase 2b trial;
4mo agoANROAlto Neuroscience Announces Pricing of $100.0 Million Underwritten Registered Direct Offering of Common StockBusiness WireAlto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging neurobiology to develop personalized and highly effective treatment
4mo agoANROAlto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on AnhedoniaBusiness Wire– Independent, peer-reviewed, placebo-controlled trial conducted by Lund University showed pramipexole significantly reduced anhedonia (primary endpoint, Hedges' g=0.62, p=0.006) – – Benefit extended to independent
5mo agoANROAlto Neuroscience Appoints Karuna Therapeutics Founder Andrew Miller, Ph.D. to Board of DirectorsBusiness WireMiller brings deep neuropsychiatry drug development and value creation experience, having led R&D at Karuna Therapeutics through its $14 billion acquisition by Bristol Myers Squibb Alto Neuroscience, Inc. ("Alto")
6mo agoANROAlto Neuroscience CEO Amit Etkin, M.D., Ph.D. Receives Columbia University Transformational Research AwardBusiness WireAlto Neuroscience, Inc. (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today congratulates founder and CEO Amit Etkin,
6mo agoANROAlto Neuroscience Reports First Quarter 2026 Financial Results and Recent Business HighlightsBusiness Wire– Phase 2b clinical trial of ALTO-207 in treatment-resistant depression (TRD) initiated – – New ALTO-101 analyses support significant effects on EEG markers of general cognition as well as a test of attention – –
6mo agoANROAlto Neuroscience Announces Participation in Upcoming Investor ConferencesBusiness WireAlto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the
6mo agoANROAlto Neuroscience Presents Phase 2a Data for ALTO-207 in Major Depressive Disorder at SOBP Annual MeetingBusiness Wire— Randomized, placebo-controlled, Phase 2a trial demonstrated robust, statistically significant antidepressant effects of ALTO-207 and favorable tolerability; supporting development of ALTO-207 in ~7 million patient
6mo agoANROAlto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant DepressionBusiness Wire— Phase 2b closely resembles PAX-D study design, which demonstrated an effect size for pramipexole more than two times larger than approved TRD therapies — — Trial design and MADRS primary endpoint aligned with FDA
7mo agoANROAlto Neuroscience Reports Topline Data from Phase 2 Proof-of-Concept Study of ALTO-101 and Highlights Pipeline AdvancementsBusiness Wire— In the proof-of-concept study, ALTO-101 did not achieve statistical significance on primary endpoint; signals observed across EEG measures including near-significant improvement in theta-ITC (p=0.052) — — Alto has
8mo agoANROAlto Neuroscience Announces $120 Million Private Placement FinancingBusiness Wire– Financing led by Commodore Capital with participation from new and existing biotech focused investors – – Alto expects to use the proceeds of the financing to support the development of ALTO-207 in Treatment
8mo agoANROAlto Neuroscience Reports Full Year 2025 Financial Results and Recent Business HighlightsBusiness Wire– Acquisition of ALTO-207 targets Treatment-Resistant Depression (TRD) with a clinically-validated mechanism; Phase 2b trial on track to be initiated in the first half of 2026 – – External PAX-D study published in The
8mo agoANROAlto Neuroscience Announces Participation at the Stifel 2026 Virtual CNS ForumBusiness WireAlto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the
8mo agoHELP CMPS RLMD ANRO+1Psychedelic Medicine Advances: Here Are Five Companies Targeting CNS DisordersPR NewswireUSA News Group News Commentary – The first psilocybin compound to achieve two positive Phase 3 results in treatment-resistant depression cleared that ...
8mo agoANROAlto Neuroscience Announces Participation in Upcoming Investor ConferencesBusiness WireAlto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the
9mo agoANROAlto Neuroscience Announces Completion of Enrollment in Phase 2 Proof-of-Concept Study of ALTO-101 in Cognitive Impairment Associated with SchizophreniaBusiness WireAlto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the completion of patient
9mo agoANROAlto Neuroscience Highlights Invited Review in American Journal of Psychiatry Establishing Neuroplasticity as a Core Driver of Psychiatric Disease and TreatmentBusiness Wire– The review provides strong scientific rationale to support Alto's drug development approach leveraging its Precision Psychiatry Platform – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage
10mo agoANROAlto Neuroscience Strengthens Intellectual Property Portfolio with Issuance of New Method-of-Treatment Patent for ALTO-207 in DepressionBusiness Wire– Issued and pending claims expected to protect ALTO-207 into the mid-2040s – Alto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision
11mo agoANROAlto Neuroscience Announces New Employee Inducement Grants Under NYSE Rule 303A.08Business WireAlto Neuroscience, Inc. ("Alto") (NYSE:ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that on December 2, 2025,
12mo agoANROAlto Neuroscience Reports Third Quarter 2025 Financial Results and Recent Business HighlightsBusiness Wire– Successful outcome from FDA meeting on ALTO-207 in treatment-resistant depression; on track to initiate Phase 2b trial in the first half of 2026 and Phase 3 trial by early 2027 – – Positive blinded pharmacokinetic
1y agoANROAlto Neuroscience to Participate in Upcoming Investor ConferencesBusiness WireAlto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that members of the
1y agoANROAlto Neuroscience Announces $50 Million Private Placement FinancingBusiness Wire– Financing led by Perceptive Advisors with participation from new and existing biotech focused investors – – Alto expects to use the proceeds of this financing to accelerate development of ALTO-207 in Treatment
1y agoANROAlto Neuroscience Announces Plans to Accelerate Development of ALTO-207 in Treatment Resistant Depression Following Successful Outcome from Recent FDA MeetingBusiness Wire– Successful outcome from recent FDA meeting guides Alto's plan to accelerate development of ALTO-207, with capital from a $50 million private placement financing expected to enable the company to initiate a Phase 3
1y agoANROAlto Neuroscience Receives FDA Fast Track Designation for ALTO-101 for the Treatment of Cognitive Impairment Associated with SchizophreniaBusiness Wire– ALTO-101, a novel PDE4 inhibitor, has demonstrated pro-cognitive effects in healthy volunteers – – Designation highlights the significant unmet need for new treatments for cognitive impairment associated with
1y agoANROINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto NeurosciencePR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alto Neuroscience, Inc. ("Alto" or the...
1y agoANROAlto Neuroscience, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before September 19, 2025 to Discuss Your Rights – ANROGlobeNewswireNEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Alto Neuroscience, Inc. (NYSE:ANRO). Shareholders who purchased shares of ANRO during the class period
1y agoANROAlto Neuroscience Announces Robust Replication of EEG Biomarker to Objectively Identify Patients with Cognitive Impairment in SchizophreniaBusiness Wire– Independent prospective analysis validates theta-band inter-trial coherence (ITC) as an important, objective measure to distinguish patients with schizophrenia from healthy individuals – – A statistically
1y agoANROINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto NeurosciencePR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alto Neuroscience, Inc. ("Alto" or the...
1y agoANROAlto Neuroscience, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - ANROPR NewswireThe Gross Law Firm issues the following notice to shareholders of Alto Neuroscience, Inc. (NYSE: ANRO). Shareholders who purchased shares of ANRO...
1y agoANROSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto NeuroscienceGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Alto To Contact Him Directly To Discuss Their Options If you purchased or
1y agoANROAlto Neuroscience, Inc. Sued for Securities Law Violations - Investors Should Contact The Gross Law Firm for More Information - ANROPR NewswireThe Gross Law Firm issues the following notice to shareholders of Alto Neuroscience, Inc. (NYSE: ANRO). Shareholders who purchased shares of ANRO...
1y agoANROShareholders of Alto Neuroscience, Inc. Should Contact The Gross Law Firm Before September 19, 2025 to Discuss Your Rights – ANROGlobeNewswireNEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Alto Neuroscience, Inc. (NYSE:ANRO). Shareholders who purchased shares of ANRO during the class period
1y agoANROINVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto NeurosciencePR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alto Neuroscience, Inc. ("Alto" or the...
1y agoANROShareholders of Alto Neuroscience, Inc. Should Contact The Gross Law Firm Before September 19, 2025 to Discuss Your Rights - ANROPR NewswireThe Gross Law Firm issues the following notice to shareholders of Alto Neuroscience, Inc. (NYSE: ANRO). Shareholders who purchased shares of ANRO...
1y agoANROThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. Lawsuit - ANROPR NewswireThe Gross Law Firm issues the following notice to shareholders of Alto Neuroscience, Inc. (NYSE: ANRO). Shareholders who purchased shares of ANRO...
1y agoANROSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto NeuroscienceGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Alto To Contact Him Directly To Discuss Their Options If you purchased or
1y agoANROSHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto NeurosciencePR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alto Neuroscience, Inc. ("Alto" or the...
1y agoANROThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. Lawsuit - ANROPR NewswireThe Gross Law Firm issues the following notice to shareholders of Alto Neuroscience, Inc. (NYSE: ANRO). Shareholders who purchased shares of ANRO...
1y agoANROAlto Neuroscience Reports Second Quarter 2025 Financial Results and Recent Business HighlightsBusiness Wire– Acquisition of potentially best-in-class dopamine agonist combination product candidates, including ALTO-207, expands precision psychiatry pipeline; guided by compelling PAX-D study results published in The Lancet
1y agoANRO CERE RAPPAlto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of DirectorsBusiness WireAlto Neuroscience, Inc. ("Alto") (NYSE:ANRO) a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced the appointment of Raymond
1y agoANROAlto Neuroscience, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm Before September 19, 2025 to Discuss Your Rights – ANROGlobeNewswireNEW YORK, Aug. 07, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Alto Neuroscience, Inc. (NYSE:ANRO). Shareholders who purchased shares of ANRO during the class period
1y agoANROAlto Neuroscience, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – ANROGlobeNewswireNEW YORK, Aug. 04, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Alto Neuroscience, Inc. (NYSE:ANRO). Shareholders who purchased shares of ANRO during the class period
1y agoANROThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. Lawsuit - ANROPR NewswireThe Gross Law Firm issues the following notice to shareholders of Alto Neuroscience, Inc. (NYSE: ANRO). Shareholders who purchased shares of ANRO...
1y agoANROANRO Investors Have the Opportunity to Lead the Alto Neuroscience Securities Fraud Lawsuit with Faruqi & Faruqi, LLPPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Alto Neuroscience, Inc. ("Alto" or the...
1y agoANROSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Alto NeuroscienceGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Alto To Contact Him Directly To Discuss Their Options If you purchased or
1y agoANROThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of September 19, 2025 in Alto Neuroscience, Inc. Lawsuit - ANROPR NewswireThe Gross Law Firm issues the following notice to shareholders of Alto Neuroscience, Inc. (NYSE: ANRO). Shareholders who purchased shares of ANRO...